HC Wainwright Lowers Soleno Therapeutics Price Target

Analysts cut price target on Soleno Therapeutics stock from $120 to $100 while maintaining a buy rating.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

HC Wainwright, a brokerage firm, has lowered its price target on shares of Soleno Therapeutics (NASDAQ:SLNO) from $120.00 to $100.00 while maintaining a "buy" rating on the stock. The new $100 price target represents a potential upside of 165.11% from the company's current trading price.

Why it matters

Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare and orphan diseases. The lowered price target from HC Wainwright suggests analysts see potential upside in the stock, even as they temper their near-term expectations.

The details

In its report, HC Wainwright cited the company's lead candidate, diazoxide choline controlled release (DCCR), which is being investigated for the treatment of Prader-Willi syndrome (PWS). Several other brokerages have also recently weighed in on Soleno Therapeutics, with some setting price targets as high as $120 and others as low as $60.

  • The new $100 price target was issued by HC Wainwright on March 4, 2026.

The players

HC Wainwright

A brokerage firm that covers Soleno Therapeutics and has lowered its price target on the stock.

Soleno Therapeutics

A clinical-stage biopharmaceutical company focused on developing therapies for rare and orphan diseases, including Prader-Willi syndrome.

Got photos? Submit your photos here. ›

The takeaway

While Soleno Therapeutics' stock price target was lowered, the company maintains a "buy" rating from HC Wainwright, suggesting analysts still see significant upside potential in the company's pipeline and lead candidate for treating Prader-Willi syndrome.